Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer

This study has been completed.
Turku University Hospital
Tampere University Hospital
FinnMedi Oy
Information provided by (Responsible Party):
BioCis Pharma Ltd Identifier:
First received: October 4, 2011
Last updated: November 9, 2012
Last verified: November 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2012
  Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)